Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

Shanghai Zhongshan Hospital1 site in 1 country498 target enrollmentJanuary 18, 2021

ConditionsCancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cancer
Sponsor: Shanghai Zhongshan Hospital
Enrollment: 498
Locations: 1
Primary Endpoint: Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

ASCEND-Gastric is a prospective, multi-omics, observational study aimed at detecting gastric cancer by combined assays for serum protein markers, deep sequencing of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA) mutation and circulating RNA. The study will enroll 498 participants, including 128 patients with benign gastric diseases and 370 patients with gastric cancer.

Registry

clinicaltrials.gov

Start Date

January 18, 2021

End Date

September 22, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shanghai Zhongshan Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.

Time Frame: 30 months

Secondary Outcomes

Sensitivity and specificity for detecting gastric cancer of a cfDNA methylation-based model, in combination with other biomarkers.(30 months)
The differences of sensitivity and specificity in gastric cancer participants at different clinical stages.(30 months)
Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively.(30 months)